Literature DB >> 31402502

T and B-cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity.

Silvia Preite1,2, Julio Gomez-Rodriguez1,2, Jennifer L Cannons1,2, Pamela L Schwartzberg1,2.   

Abstract

Phosphatidylinositol 3 kinases (PI3K) are a family of lipid kinases that are activated by a variety of cell-surface receptors, and regulate a wide range of downstream readouts affecting cellular metabolism, growth, survival, differentiation, adhesion, and migration. The importance of these lipid kinases in lymphocyte signaling has recently been highlighted by genetic analyses, including the recognition that both activating and inactivating mutations of the catalytic subunit of PI3Kδ, p110δ, lead to human primary immunodeficiencies. In this article, we discuss how studies on the human genetic disorder "Activated PI3K-delta syndrome" and mouse models of this disease (Pik3cdE1020K/+ mice) have provided fundamental insight into pathways regulated by PI3Kδ in T and B cells and their contribution to lymphocyte function and disease, including responses to commensal bacteria and the development of autoimmunity and tumors. We highlight critical roles of PI3Kδ in T follicular helper cells and the orchestration of the germinal center reaction, as well as in CD8+ T-cell function. We further  present data demonstrating the ability of the AKT-resistant FOXO1AAA mutant to rescue IgG1 class switching defects in Pik3cdE1020K/+ B cells, as well as data supporting a role for PI3Kδ in promoting multiple T-helper effector cell lineages. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  APDS/PASLI; T and B lymphocytes; autoimmunity; immunodeficiency; phosphatidylinositol 3 kinase

Mesh:

Substances:

Year:  2019        PMID: 31402502     DOI: 10.1111/imr.12790

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  16 in total

Review 1.  Hallmarks of T cell aging.

Authors:  Maria Mittelbrunn; Guido Kroemer
Journal:  Nat Immunol       Date:  2021-05-13       Impact factor: 25.606

Review 2.  Role of inhibitory signaling in peripheral B cell tolerance.

Authors:  Andrew Getahun
Journal:  Immunol Rev       Date:  2022-02-06       Impact factor: 12.988

3.  How immunodeficiency can lead to malignancy.

Authors:  Sung-Yun Pai; Kathryn Lurain; Robert Yarchoan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Control of CD4+ T Cell Differentiation and Function by PI3K Isoforms.

Authors:  Benjamin Cameron; Syed Aymaan Zaheer; Margarita Dominguez-Villar
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

Review 5.  Autoimmune Cytopenias in Common Variable Immunodeficiency Are a Diagnostic and Therapeutic Conundrum: An Update.

Authors:  Sanchi Chawla; Prabal Barman; Rahul Tyagi; Ankur Kumar Jindal; Saniya Sharma; Amit Rawat; Surjit Singh
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

6.  Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses.

Authors:  Ke Xu; Na Yin; Min Peng; Efstathios G Stamatiades; Sagar Chhangawala; Amy Shyu; Peng Li; Xian Zhang; Mytrang H Do; Kristelle J Capistrano; Chun Chou; Christina S Leslie; Ming O Li
Journal:  Immunity       Date:  2021-05-11       Impact factor: 31.745

Review 7.  Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review.

Authors:  Stephen A Schworer; Olivia L Francis; Steven M Johnson; Benjamin D Smith; Stuart H Gold; Andrew B Smitherman; Eveline Y Wu
Journal:  J Pediatr Hematol Oncol       Date:  2021-11-01       Impact factor: 1.289

Review 8.  Beyond monogenetic rare variants: tackling the low rate of genetic diagnoses in predominantly antibody deficiency.

Authors:  Emily S J Edwards; Julian J Bosco; Samar Ojaimi; Robyn E O'Hehir; Menno C van Zelm
Journal:  Cell Mol Immunol       Date:  2020-08-17       Impact factor: 11.530

Review 9.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

10.  Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs.

Authors:  Yanjun Jia; Qiuyun Yang; Yanping Wang; Wenyan Li; Xuemei Chen; Tao Xu; Zhirui Tian; Minxuan Feng; Liang Zhang; Wenjing Tang; Na Tian; Lina Zhou; Wenxia Song; Xiaodong Zhao
Journal:  Cell Mol Immunol       Date:  2020-02-25       Impact factor: 22.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.